Vestal Point Capital LP increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 172.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,075,000 shares of the company's stock after buying an additional 680,000 shares during the quarter. Dianthus Therapeutics comprises approximately 1.4% of Vestal Point Capital LP's holdings, making the stock its 27th largest holding. Vestal Point Capital LP owned approximately 3.63% of Dianthus Therapeutics worth $23,435,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of DNTH. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics in the fourth quarter worth $32,735,000. Braidwell LP lifted its position in Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after buying an additional 712,902 shares during the last quarter. Octagon Capital Advisors LP lifted its position in Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after buying an additional 363,500 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $3,924,000. Finally, Alliancebernstein L.P. increased its stake in shares of Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock valued at $25,283,000 after buying an additional 136,633 shares during the period. 47.53% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
DNTH has been the topic of several research reports. Guggenheim restated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, Robert W. Baird dropped their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $53.00.
View Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
NASDAQ DNTH traded up $0.06 during trading hours on Friday, reaching $18.42. The stock had a trading volume of 234,992 shares, compared to its average volume of 273,124. The stock has a fifty day moving average of $19.13 and a 200 day moving average of $21.83. The stock has a market cap of $592.39 million, a P/E ratio of -7.37 and a beta of 1.48. Dianthus Therapeutics, Inc. has a 52-week low of $13.37 and a 52-week high of $32.27.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Dianthus Therapeutics Company Profile
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
